↓ Skip to main content

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk

Overview of attention for article published in Cardiovascular Diabetology, March 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
104 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Published in
Cardiovascular Diabetology, March 2017
DOI 10.1186/s12933-017-0515-9
Pubmed ID
Authors

Katherine Kearney, Darren Tomlinson, Kerrie Smith, Ramzi Ajjan

Abstract

An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed of a skeleton of fibrin fibres with cellular elements embedded in this network. Diabetes is characterised by quantitative and qualitative changes in coagulation proteins, which collectively increase resistance to fibrinolysis, consequently augmenting thrombosis risk. Current long-term therapies to prevent arterial occlusion in diabetes are focussed on anti-platelet agents, a strategy that fails to address the contribution of coagulation proteins to the enhanced thrombotic milieu. Moreover, antiplatelet treatment is associated with bleeding complications, particularly with newer agents and more aggressive combination therapies, questioning the safety of this approach. Therefore, to safely control thrombosis risk in diabetes, an alternative approach is required with the fibrin network representing a credible therapeutic target. In the current review, we address diabetes-specific mechanistic pathways responsible for hypofibrinolysis including the role of clot structure, defects in the fibrinolytic system and increased incorporation of anti-fibrinolytic proteins into the clot. Future anti-thrombotic therapeutic options are discussed with special emphasis on the potential advantages of modulating incorporation of the anti-fibrinolytic proteins into fibrin networks. This latter approach carries theoretical advantages, including specificity for diabetes, ability to target a particular protein with a possible favourable risk of bleeding. The development of alternative treatment strategies to better control residual thrombosis risk in diabetes will help to reduce vascular events, which remain the main cause of mortality in this condition.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 104 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 13%
Researcher 13 13%
Student > Ph. D. Student 12 12%
Student > Master 11 11%
Student > Postgraduate 8 8%
Other 19 18%
Unknown 27 26%
Readers by discipline Count As %
Medicine and Dentistry 34 33%
Biochemistry, Genetics and Molecular Biology 10 10%
Agricultural and Biological Sciences 10 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Engineering 4 4%
Other 9 9%
Unknown 32 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2017.
All research outputs
#13,907,273
of 23,576,969 outputs
Outputs from Cardiovascular Diabetology
#719
of 1,467 outputs
Outputs of similar age
#161,383
of 308,894 outputs
Outputs of similar age from Cardiovascular Diabetology
#18
of 29 outputs
Altmetric has tracked 23,576,969 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,467 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,894 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.